Santen Pharmaceutical Co., Ltd. (4536.T)
JPY 1548.0
(-0.51%)
JPY 1548.0
(-0.51%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 56.45 Billion JPY | 441.21% |
| 2022 | 14.29 Billion JPY | -75.97% |
| 2021 | 54.52 Billion JPY | 75.65% |
| 2020 | 30 Billion JPY | -39.92% |
| 2019 | 49.41 Billion JPY | -10.37% |
| 2018 | 54.09 Billion JPY | 12.6% |
| 2017 | 50.35 Billion JPY | 16.92% |
| 2016 | 39.99 Billion JPY | -52.08% |
| 2015 | 88.9 Billion JPY | 109.51% |
| 2014 | 42.91 Billion JPY | 34.61% |
| 2013 | 33.2 Billion JPY | 10.8% |
| 2012 | 28.88 Billion JPY | -6.03% |
| 2011 | 30.76 Billion JPY | -10.85% |
| 2010 | 34.08 Billion JPY | 4.92% |
| 2009 | 32.08 Billion JPY | 62.7% |
| 2008 | 20.09 Billion JPY | -20.51% |
| 2007 | 25.17 Billion JPY | -0.79% |
| 2006 | 26.24 Billion JPY | -2.53% |
| 2005 | 25.58 Billion JPY | 10.6% |
| 2004 | 23.68 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 17.86 Billion JPY | 157.81% |
| 2023 Q3 | 14.87 Billion JPY | -10.38% |
| 2023 Q2 | 16.59 Billion JPY | -2.77% |
| 2023 Q1 | 17.06 Billion JPY | 59.68% |
| 2023 FY | - JPY | 441.21% |
| 2023 Q4 | 15.66 Billion JPY | 5.3% |
| 2022 Q1 | 13.66 Billion JPY | -8.47% |
| 2022 FY | - JPY | -75.97% |
| 2022 Q4 | 10.68 Billion JPY | -16.23% |
| 2022 Q3 | 12.75 Billion JPY | 154.96% |
| 2022 Q2 | -23.21 Billion JPY | -269.89% |
| 2021 Q3 | 11.81 Billion JPY | -14.84% |
| 2021 Q1 | 13.64 Billion JPY | 238.8% |
| 2021 Q2 | 13.87 Billion JPY | 1.69% |
| 2021 Q4 | 14.93 Billion JPY | 26.38% |
| 2021 FY | - JPY | 75.65% |
| 2020 Q1 | 12.66 Billion JPY | 42.33% |
| 2020 Q4 | -9.82 Billion JPY | -175.13% |
| 2020 Q3 | 13.08 Billion JPY | -11.35% |
| 2020 Q2 | 14.75 Billion JPY | 16.55% |
| 2020 FY | - JPY | -39.92% |
| 2019 Q4 | 8.89 Billion JPY | -36.78% |
| 2019 Q3 | 14.07 Billion JPY | 1.07% |
| 2019 Q2 | 13.92 Billion JPY | 0.83% |
| 2019 Q1 | 13.8 Billion JPY | -2.92% |
| 2019 FY | - JPY | -10.37% |
| 2018 Q4 | 14.22 Billion JPY | -10.32% |
| 2018 FY | - JPY | 12.6% |
| 2018 Q2 | 13.61 Billion JPY | 2.66% |
| 2018 Q1 | 13.26 Billion JPY | 14.32% |
| 2018 Q3 | 15.86 Billion JPY | 16.48% |
| 2017 Q2 | 11.74 Billion JPY | -22.57% |
| 2017 Q1 | 15.17 Billion JPY | 99.86% |
| 2017 Q3 | 12.06 Billion JPY | 2.72% |
| 2017 Q4 | 11.6 Billion JPY | -3.85% |
| 2017 FY | - JPY | 16.92% |
| 2016 Q2 | 10.43 Billion JPY | -23.46% |
| 2016 Q4 | 7.59 Billion JPY | -38.04% |
| 2016 FY | - JPY | -52.08% |
| 2016 Q1 | 13.63 Billion JPY | 65.38% |
| 2016 Q3 | 12.25 Billion JPY | 17.42% |
| 2015 Q4 | 8.24 Billion JPY | -29.59% |
| 2015 FY | - JPY | 109.51% |
| 2015 Q1 | 13.43 Billion JPY | 5.36% |
| 2015 Q2 | 56.94 Billion JPY | 323.88% |
| 2015 Q3 | 11.7 Billion JPY | -79.44% |
| 2014 Q3 | 13.54 Billion JPY | 31.22% |
| 2014 Q4 | 12.75 Billion JPY | -5.85% |
| 2014 FY | - JPY | 34.61% |
| 2014 Q1 | 6.5 Billion JPY | 30.37% |
| 2014 Q2 | 10.32 Billion JPY | 58.73% |
| 2013 FY | - JPY | 10.8% |
| 2013 Q1 | 9.07 Billion JPY | 73.42% |
| 2013 Q2 | 7.57 Billion JPY | -16.54% |
| 2013 Q3 | 10.37 Billion JPY | 36.97% |
| 2013 Q4 | 4.98 Billion JPY | -51.93% |
| 2012 FY | - JPY | -6.03% |
| 2012 Q3 | 8.63 Billion JPY | 11.89% |
| 2012 Q2 | 7.71 Billion JPY | 5.45% |
| 2012 Q4 | 5.23 Billion JPY | -39.37% |
| 2012 Q1 | 7.31 Billion JPY | 30.02% |
| 2011 Q1 | 8.85 Billion JPY | -5.93% |
| 2011 FY | - JPY | -10.85% |
| 2011 Q2 | 7.55 Billion JPY | -14.7% |
| 2011 Q3 | 8.71 Billion JPY | 15.31% |
| 2011 Q4 | 5.62 Billion JPY | -35.41% |
| 2010 Q4 | 9.41 Billion JPY | 3.71% |
| 2010 FY | - JPY | 4.92% |
| 2010 Q1 | 7.89 Billion JPY | 60.51% |
| 2010 Q3 | 9.07 Billion JPY | 12.03% |
| 2010 Q2 | 8.1 Billion JPY | 2.61% |
| 2009 Q4 | 4.92 Billion JPY | -33.05% |
| 2009 Q2 | 9.27 Billion JPY | -18.23% |
| 2009 Q3 | 7.34 Billion JPY | -20.72% |
| 2009 Q1 | 11.33 Billion JPY | 148.32% |
| 2009 FY | - JPY | 62.7% |
| 2008 Q2 | 5.9 Billion JPY | 0.0% |
| 2008 FY | - JPY | -20.51% |
| 2008 Q4 | 4.56 Billion JPY | -37.76% |
| 2008 Q3 | 7.33 Billion JPY | 24.2% |
| 2007 FY | - JPY | -0.79% |
| 2006 FY | - JPY | -2.53% |
| 2005 FY | - JPY | 10.6% |
| 2004 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 117.59 Billion JPY | 51.988% |
| Astellas Pharma Inc. | 195.34 Billion JPY | 71.098% |
| Chugai Pharmaceutical Co., Ltd. | 470.91 Billion JPY | 88.011% |
| Ono Pharmaceutical Co., Ltd. | 178.43 Billion JPY | 68.36% |
| JCR Pharmaceuticals Co., Ltd. | 10.72 Billion JPY | -426.209% |
| Daiichi Sankyo Company, Limited | 305.45 Billion JPY | 81.517% |
| Otsuka Holdings Co., Ltd. | 224.19 Billion JPY | 74.818% |
| Perseus Proteomics Inc. | -892 Million JPY | 6429.26% |